Advertisement

Autoimmune Muskelerkrankungen

Chapter

Zusammenfassung

Die idiopathischen inflammatorischen Myopathien (IIM) umfassen die Dermatomyositis (DM), die immunogen nekrotisierenden Myopathien (INM), die Antisynthetasesyndrom(ASS)-assoziierte Myositis, die sporadische Einschlusskörpermyositis (sIBM) und die Polymyositis (PM). Dieses Kapitel stellt die Klinik, aktuelle serologische Autoantikörperprofile, EMG-Befunde, die Bildgebung und die Muskelbiopsiediagnostik dar. Dazu werden die aktuellen Behandlungsoptionen zusammengefasst. Differenzialdiagnostisch wichtige Erkrankungen werden einbezogen. Chronische Myositiden müssen ggf. bioptisch und molekulargenetisch von hereditären Myopathien abgegrenzt werden. Wichtigste Neuerungen des diagnostischen Vorgehens und Informationen zum Krankheitsverlauf werden dargestellt.

Literatur

  1. Allenbach Y, Benveniste O (2013) Acquired necrotizing myopathies. Curr Opin Neurol 26:554–560CrossRefGoogle Scholar
  2. Allenbach Y, Benveniste O (2014) Autoantibody profile in myositis. Rev Med Interne 35:437–443CrossRefGoogle Scholar
  3. Allenbach Y, Leroux G, Suarez-Calvet X, Preusse C, Gallardo E, Hervier B, Rigolet A, Hie M, Pehl D, Limal N, Hufnagl P, Zerbe N, Meyer A, Aouizerate J, Uzunhan Y, Maisonobe T, Goebel HH, Benveniste O, Stenzel W (2016a) Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression. Am J Pathol 186:691–700CrossRefGoogle Scholar
  4. Allenbach Y, Keraen J, Bouvier AM, Jooste V, Champtiaux N, Hervier B, Schoindre Y, Rigolet A, Gilardin L, Musset L, Charuel JL, Boyer O, Jouen F, Drouot L, Martinet J, Stojkovic T, Eymard B, Laforet P, Behin A, Salort-Campana E, Fain O, Meyer A, Schleinitz N, Mariampillai K, Grados A, Benveniste O (2016b) High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 139:2131–2517CrossRefGoogle Scholar
  5. Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, Stojkovic T, Leite MI, Allenbach Y, Herson S, Brady S, Eymard B, Hilton-Jones D (2011) Long-term observational study of sporadic inclusion body myositis. Brain 134:3176–3184CrossRefGoogle Scholar
  6. Benveniste O, Stenzel W, Hilton-Jones D, Sandri M, Boyer O, Engelen BG van (2015) Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol 129:611–624CrossRefGoogle Scholar
  7. Bird HA, Esselintex W, Dixon ASJ, Moval AG, Wood PHN (1979) An evaluation of criteria for polymyalgia rheumatica. Ann Rheum 38:434–439CrossRefGoogle Scholar
  8. Bohan A, Peter JB (1975a) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407CrossRefGoogle Scholar
  9. Bohan A, Peter JB (1975b) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347CrossRefGoogle Scholar
  10. De Bleecker JL, De Paepe B, Aronica E, Visser M de, Amato A, Benveniste O, De Bleecker J, Boer O de, Dimachkie M, Gherardi R, Goebel HH, Hilton-Jones D, Holton J, Lundberg IE, Mammen A, Mastaglia F, Nishino I, Rushing E, Schroder HD, Selcen D, Stenzel W (2015) 205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies part II 28–30 March 2014, Naarden, The Netherlands. Neuromuscul Disord 25:268–272CrossRefGoogle Scholar
  11. Hengstman GJ, Laak HJ ter, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, Doria A, Mosca M, Venrooij WJ van, Engelen BG van (2006) Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65:1635–1638CrossRefGoogle Scholar
  12. Hida A, Yamashita T, Hosono Y, Inoue M, Kaida K, Kadoya M, Miwa Y, Yajima N, Maezawa R, Arai S, Kurasawa K, Ito K, Shimada H, Iwanami T, Sonoo M, Hatanaka Y, Murayama S, Uchibori A, Chiba A, Aizawa H, Momoo T, Nakae Y, Sakurai Y, Shiio Y, Hashida H, Yoshizawa T, Sakiyama Y, Oda A, Inoue K, Takeuchi S, Iwata NK, Date H, Masuda N, Mikata T, Motoyoshi Y, Uesaka Y, Maeda MH, Nakashima R, Tsuji S, Kwak S, Mimori T, Shimizu J (2016) Anti-TIF1-gamma antibody and cancer-associated myositis: a clinicohistopathologic study. Neurology 87:299–308CrossRefGoogle Scholar
  13. Holmgren AR, Matteson EL (2006) Lyme myositis. Arthritis Rheum 54:2697–2700CrossRefGoogle Scholar
  14. Kang EH, Lee SJ, Ascherman DP, Lee YJ, Lee EY, Lee EB, Song YW (2016) Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatology (Oxford) 55(9):1631–1641CrossRefGoogle Scholar
  15. Leitlinie Myositis Deutsche Gesellschaft für Neurologie. https://www.dgn.org/leitlinien/3011-ll-69-ll-myositissyndrome
  16. Lünemann JD, Schmidt J, Schmid D, Barthel K, Wrede A, Dalakas MC, Munz C (2007) Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 61:476–483CrossRefGoogle Scholar
  17. Mammen AL, Gaudet D, Brisson D, Christopher-Stine L, Lloyd TE, Leffell MS, Zachary AA (2012) Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 64:1233–1237CrossRefGoogle Scholar
  18. Meulen MF van der, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, Dinant HJ, Linssen WH, Wokke JH, de Visser M (2003) Polymyositis: an overdiagnosed entity. Neurology 61:316–321CrossRefGoogle Scholar
  19. Naschitz JE, Boss JH, Misselevich I, Yeshurun D, Rosner I (1996) The fasciitis-panniculitis syndromes. Clinical and pathologic features. Medicine 75:6–16PubMedGoogle Scholar
  20. Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL (2015) The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis. J Rheumatol 42:1448–1454CrossRefGoogle Scholar
  21. Rose MR (2013) 188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul Disord 23:1044–1055CrossRefGoogle Scholar
  22. Stenzel W, Goebel HH, Aronica E (2011) Review: immune-mediated necrotizing myopathies – a heterogeneous group of diseases with specific myopathological features. Neuropathol Appl Neurobiol 38:632–646CrossRefGoogle Scholar
  23. Troyanov Y, Targoff IN, Payette MP, Raynauld JP, Chartier S, Goulet JR, Bourre-Tessier J, Rich E, Grodzicky T, Fritzler MJ, Joyal F, Koenig M, Senecal JL (2014) Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine (Baltimore) 93:318–332CrossRefGoogle Scholar
  24. Zierz S, Jerusalem J (2014) Muskelerkrankungen, 4. Aufl. Thieme, StuttgartGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Friedrich-Bauer-Institut an der Neurologischen KlinikKlinikum der Universität MünchenMünchenDeutschland

Personalised recommendations